Compare Sanofi SA (SNY) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs TKO Group Holdings Inc — how do they compare? Sanofi SA trades at $40.04 (market cap $95.18B), while TKO Group Holdings Inc trades at $179 (market cap $13.28B). The key difference: Sanofi SA is far larger — about 7.2× TKO Group Holdings Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and TKO Group Holdings Inc for 30 Days on average.
| SNY | TKO | |
|---|---|---|
Market Cap | $95.18B | $13.28B |
Volume | 2,995,646 | 857,653 |
Sector | Health | Media |
52-Week High | $52.34 | $224.96 |
52-Week Low | $39.51 | $175.58 |
Typical Hold Time | 94 Days | 30 Days |
Enterprise Value | $114.48B | $17.64B |
Dividend Yield | 6.01% | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
TKO trades at $179.38, up 0.41% on the day, but technical indicators signal a bearish trend with the stock near a 52-week low of $174.58 (Defense World, 2026-10-02). The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year guidance. Revenue growth remains solid, with 2026 projections at $5.3B, though profitability margins are thin at 4.33% net income margin. A quarterly dividend of $0.79 was declared for payment in September 2026.
Wall Street maintains a bullish stance with 89% buy ratings and a $227 consensus price target, implying significant upside. Key risks include execution on media rights deals, competitive pressures in sports entertainment, and reliance on live events. The stock's high P/E of 63.73 suggests growth expectations must be met to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
